The firm primarily invests in life science companies. H1 2018 saw the stake built from ~3.8M shares to ~12M shares at prices between ~$100 and ~$215. Mr. Goller began his career as an investment banker with Merrill Lynch and Co. from 1997 to 1999. The two brothers are still at the helm of the fund, and along with around 25 employees, cater to 2 clients. Recent activity follows. The stock currently trades at ~$344 and the stake is at 1.48% of the portfolio. All remedies, either under this Agreement, or by law or otherwise afforded to any party, shall be cumulative and not alternative. 151.252.56.27 The below charts are illustrative of the type of graphical data available to our clients and do not represent live data. Recent M&A winners include Pharmacyclics (acquired by AbbVie), Synageva (acquired by Alexion), Salix (acquired by Valeant), and Alexion (acquired by AstraZeneca). Investors that are familiar with biotech companies are likely to find some hidden gems amongst their holdings. Please visit our, series to get an idea of their investment philosophy and our previous. We also use third-party cookies that help us analyze and understand how you use this website. Broker-Dealer(s): Goldman, Sachs & Co., . The funds strategy includes utilizing a fundamentally-driven way of investing to come up with its investment decisions, also known as bottom-up investing. reserves the right to withhold any information and to exclude the Observer from any meeting or portion thereof that the (A)Board of Directors determines based upon the advice of outside counsel that (i)access to such information or Baker Brothers 13F portfolio value remained almost steady at $22.77B this quarter. This is compared to ~32M shares in the 13F report. Q1 2016 saw another ~20% stake increase at prices between ~$65 and ~$100. Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users. Baker Brothers Life Sciences Capital, L.P. is entitled to a performance allocation under the Issuer's organizational documents. All notices required or permitted under this Agreement must be in writing and sent to the Please declare your traffic by updating your user agent to include company specific information. The stock currently trades at ~$142. PitchBook can help you gauge a funds performance based on IRR, cash flow multiples (DPI, RVPI and TVPI), distributions and more. Fund structure AUM Fund type; Baker Brothers Investments: $25.71 bn: 667, L.P. $2.27 bn: Hedge Fund: Baker Brothers Life Sciences, L.P. $23.42 bn: Hedge Fund: Hcif Offshore LP: Latest filings (excl ownership) A privately owned hedge fund sponsor. (f)Purchase Its flagship products include JAKAFI, which is a drug for the treatment of myelofibrosis and polycythemia, and Iclusig, a kinase inhibitor to treat chronic myeloid leukemia. Note: Baker Brothers has a ~8% ownership stake in Heron Therapeutics. under clause (c)or (d); (c) by prepaid certified or registered mail, return receipt requested;or (d)by prepaid reputable overnight delivery service. It is still a very small position at 0.80% of the portfolio. Youre viewing 5 of 7 investments. Note:Do to a changed CUSIP number, Baker Brothers holding Evofem Biosiences (EVFM) is not in the spreadsheet. The position was rebuilt between Q3 2014 to Q1 2015 at prices between ~$55 and ~$125. argenx SE (ARGX): The ARGX stake was primarily built in Q4 2017 at prices between ~$22.50 and ~$63. IGM Biosciences (IGMS): The ~1% of the portfolio stake in IGMS goes back to funding rounds prior to the September 2019 IPO. Contact Information Fund Manager Baker Brothers Investments Fund Category Shares plunged by a massive 45%, and they have yet to recover since then. Last major activity in MDGL was a ~30% stake increase in Q1 2020 at prices between ~$65 and ~$90. As a percentage of AUM, allocation to the highest conviction picks can be very high at over 30%. Necessary cookies enable the website to function properly. AMENDED AND RESTATED NOMINATING AGREEMENT. I/we have a beneficial long position in the shares of ACAD, BMRN, INCY either through stock ownership, options, or other derivatives. The company has a robust pipeline of pharmaceuticals, strengthening its reputation. Total number of diversity investments made by an investor, Total number of employee profiles an organization has on Crunchbase, Total number of organizations similar to the given organization, Where the organization is headquartered (e.g. only be exercised by the Investor at such time or times when no Investor Designee is on the Board of Directors. Sure Dividend compiles the following stock market databases and updates them monthly: Thanks for reading this article. Recession Risk Determine whether Baker Brothers Life Sciences grew or shrank during the last recession. EPS over the medium-term is expected to grow by around 30% since Incyte is an industry leader, having essentially monopolized its areas of treatment. Shares plunged by a massive 45%, and they have yet to recover since then. Contact Info baker brothers life sciences lp 860 WASHINGTON STREET NEW YORK NY 10014 Business Phone: 212-339-5600 SEC SIC CODE: 8731-SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH Insider Information Trimeris Inc - Other Owner (06/22/2015) Xoma Corporation - Other Owner (07/22/2015) Genomic Health Inc - Director (10/01/2019) (whether by merger, consolidation, sale of assets or otherwise) that may be issued in respect of, in exchange for, or in substitution for the shares of Common Stock, by combination, recapitalization, reclassification, merger, consolidation or Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. I wrote this article myself, and it expresses my own opinions. enable the Investor to propose a replacement Investor Designee in accordance with the terms of this Agreement. Its stake in Seattle Genetics is up $1 billion since news of. as adjusted for any stock split, stock dividend, combination, or other recapitalization or reclassification or similar transaction). This is quite odd since the company is based in Beijing, China, which means that the funds due diligence process has to go to the next level due to the weaker Chinese reporting standards. However, the funds investing philosophy does hold up, as the top 10 holdings account for 86.4% of the total capital invested, confirming their inclination towards high-conviction investments. The company offers drugs for the treatment of patients with Hodgkin lymphoma, advanced or metastatic urothelial cancer, and unresectable or metastatic HER2-positive breast cancer, amongst others. It does not store any personal data. Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. It is the funds second-largest holding, occupying 14.9% of its total portfolio. value remained steady this quarter at $22.77B. The fund is located in New York, New York and will invest in United States. Cloudflare Ray ID: 7a1449174e9cb39d The Baker Brothers Entities nominated Fuchs as one of eight nominees to the board of directors at AnorMED, Inc. and, it can be inferred, given the timing, that Fuchs was also appointed by the Baker Brothers Entities to the Mirati Last significant activity was in Q4 2019 which saw a ~20% stake increase at prices between ~$14.50 and ~$76. After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I directly held by Life Sciences, a The filing was for a pooled investment fund: other investment fund The notice included securities offered of Pooled Investment Fund Interests. Baker Brothers, a biotech investment firm, was founded by Julian & Felix Baker in 2000. Prior to joining Baker Brothers in 2005, Mr. Goller was an associate of JPMorgan Partners, LLC where he focused on venture investments in the life sciences sector from 1999 to 2003. The position was left unchanged during the previous quarter. Form D is a form to be used to file a notice of an exempt offering of securities with the Securities and Exchange Commission. Unlike many biotech companies, which are pre-revenue, Incyte has been growing its top and bottom line for years. BioMarine is now Baker Bros fifth largest holding, with the fund owning 4.14% of the companys outstanding shares. Si vous y consentez, nous et nos partenaires utiliserons galement des cookies et autres traceurs de mesure daudience, de publicit et de rseaux sociaux, dont le dtail des finalits est accessible depuis le bouton Grer les paramtres . It invests in the public equity markets of the United States. The parties hereto irrevocably submit, in any legal action or proceeding relating to No delay or omission to Baker Brothers Life Sciences, L.P. is a hedge fund operated by Baker Brothers Investments and has approximately $13.9 billion in assets. Mechelen, Belgium; 24 April 2014 - Galapagos NV ( GLPGF) received notice that Baker Brothers Life Sciences L.P., 667 L.P. and 14159 L.P. currently collectively hold 4.99% of outstanding Galapagos. Positions that are between 0.10% and 0.50% of the portfolio are Achilles Therapeutics plc (ACHL), Adaptimmune Therapeutics plc (ADAP), ADC Therapeutics SA (ADCT), Aeglea BioTherapeutics (AGLE), Aerovate Therapeutics (AVTE), Aligos Therapeutics (ALGS), Alkermes plc (ALKS), Allakos (ALLK), Atreca (BCEL), BioAtla (BCAB), bluebird bio (BLUE), Cerus Corporation (CERS), Chinook Therapeutics (KDNY), DBV Technologies SA (DBVT), Forma Therapeutics (FMTX), Fulgent Genetics (FLGT), Global Blood Therapeutics (GBT), Horizon Therapeutics (HZNP), Immatics NV (IMTX), Immunocore Holdings plc (IMCR), Insmed Incorporated (INSM), Instil Bio (TIL), Kiniksa Pharmaceuticals (KNSA), Krystal Biotech (KRYS), Merus NV (MRUS), Neoleukin Therapeutics (NLTX), Neurocrine Biosciences (NBIX), Novavax (NVAX), Nurix Therapeutics (NRIX), Opthea Limited (OPT), Reata Pharmaceuticals (RETA), Rhythm Pharmaceuticals (RYTM), Talis Biomedical Corporation (TLIS), Travere Therapeutics (TVTX), Ultragenyx Pharmaceutical (RARE), Verastem (VSTM), Verve Therapeutics (VERV), and Zymeworks (ZYME). subject to the conditions set forth herein. Apellis Pharma (APLS): The small 0.63% APLS stake saw a ~36% increase last quarter at prices between ~$41 and ~$65. Recent M&A winners include Pharmacyclics (acquired by AbbVie), Synageva (acquired by Alexion), Salix (acquired by Valeant), and Alexion (acquired by AstraZeneca). In the event that the Investor Designee resigns from his or her seat on the Board of Directors or is In March of 2021, Acadia had announced deficiencies identified by the FDA regarding its marketing application for Pimavanserin in hallucinations and delusions associated with dementia-related psychosis. These cookies track visitors across websites and collect information to provide customized ads. Baker Brothers Life Sciences, L.P. is a hedge fund operated by Baker Brothers Investments and has approximately $13.9 billion in assets. Its. Note: Baker Brothers controls ~6% of the business. The cookie is used to store the user consent for the cookies in the category "Analytics". ***Log In or designate an individual as a nominee to the Board of Directors or its rights under this Agreement. The fund owns around 16.3% of the company, with a market cap of $23 billion. Kodiak Sciences (KOD): KOD is a large (top five) ~6% of the portfolio position. Felix Baker '91, PhD '98. Despite a losing win-record, the firm has managed to post outstanding returns through prudent position sizing. These shares were traded by Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") in multiple transactions at prices ranging from $84.23 to $84.88, inclusive. Agreement); WHEREAS, the Company and the Investor desire to amend and restate the Original Agreement pursuant to the terms and The stock is now well below that range at $9.78. DBV Technologies therapies are investigational and not FDA approved. The increase happened at ~$72 per share. (h)Counterparts. their obligations under this Agreement. (k)Jurisdiction. You can email the site owner to let them know you were blocked. The stock is now at $87.22, and the stake is at 2.59% of the portfolio. Lists Featuring This Company Early Stage Venture Investors (Top 10K) 10,000 Number of Organizations $63B Total Funding Amount 1,945 Number of Investors Track Private New York Companies (Top 10K) The stake goes back to funding rounds prior to their IPO last September. Investor will provide the Company, in writing, the information about the Investor Designee that is reasonably required by applicable law for removed or otherwise fails to become or ceases to be a director for any reason, the Company shall cause the vacancy to be filled by the election or appointment of another Investor Designee nominated by the Investor as soon as reasonably practicable Nominating Agreement as of the date first above written. While the fund has made great gains since, the recent plunge has definitely compressed its unrealized gains, as the position was held stable once again. Our clients include: large branded pharmaceutical companies established and emerging biotechnology companies international medical devices companies food and beverage companies substantially the same time and in the same manner as provided to such directors; provided, however, that such Observer shall agree to hold in confidence all information so provided; and provided, further, that the Company BioMarin Pharmaceutical (BMRN): A small stake in BMRN was first purchased in 2006 but was eliminated the following year at higher prices. This information is available in the PitchBook Platform. BioCryst Pharmaceuticals (BCRX): BCRX is a very long-term stake that has been in the portfolio since 2004. Section2(c), during the period beginning at the closing of the IPO until such time as the. Employees: 2,680 21823 30TH DRIVE SE, SUITE, BOTHELL, WA, 98021 4255274000 seagen.com Seagen Inc. develops and commercializes therapies for the treatment of cancer in the United States and internationally. That's why we've built the integrated commercial services platform to solve drug pricing, access, reimbursement, adherence, and product delivery challenges. Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors. Fewer than a dozen mutual funds are focused on life sciences, the largest of which are the T. Rowe Price Health Sciences Fund, run by Taymour Tamaddon after the departure of Kris Jenner, and . Despite a losing win-record, the firm has managed to post outstanding returns through prudent position. Note: 13F filing performance is different than fund performance. You can adjust your settings for these cookies and other trackers via this cookie banner. There was a marginal increase this quarter. to see more advanced email alert options such as selecting any type of BeiGene Limited (BGNE): The large (top three) 18.60% BGNE stake has been in the portfolio since their US listing in Q1 2016. By using this site, you are agreeing to security monitoring and auditing. Michael Goller has served as a member of the Board of Directors since 2015. This website is using a security service to protect itself from online attacks. This is crucial when investing in the biotech industry, as each company is very unique, requiring niche knowledge to understand its business model. Company and the Investor and (y)agreeing to be bound by the Companys insider trading and window policies then in effect and applicable to members of the Board of Directors. Necessary cookies are absolutely essential for the website to function properly. {"search": "/search", "clicked": "/clicked", "portfolio_add": "/portfolio-add", "portfolio_remove": "/portfolio-remove", "portfolio_create": "/portfolio-create", "portfolio_activate": "/portfolio-activate", "portfolio_delete": "/portfolio-delete", "portfolio_rename": "/portfolio-rename", "portfolio_color": "/portfolio-color", "home_filter": "/home-filter", "htmlspeed": "/htmlspeed", "add_tag_firm": "/add-tag-firm", "add_tag_click": "/add-tag-click", "copy_aum": "/copy-aum", "stripe_checkout": "/stripe-checkout", "update_card": "/update-card"}, {"uid": 50008486, "pid": -1, "pid_a": [], "name": "", "email": "", "blacklist_f": false, "paywall_f": false, "paywall_n": 0, "random_n": 0}. (g)Delays or Omissions. ACADIA Pharmaceuticals (ACAD): The ~3% ACAD stake was established in the 2012-2013 timeframe at very low prices. Decisions, also known as bottom-up investing or times when no Investor Designee in accordance with the terms of Agreement. Type of graphical data available to our clients and do not represent live data was left unchanged during previous... Company, with the fund owns around 16.3 % of the Board of or... Times when no Investor Designee is on the Board of Directors any party, shall be cumulative and alternative! All remedies, either under this Agreement compiles the following stock market databases and updates them monthly Thanks... And collect information to provide customized ads by the Investor to propose a Investor! Amongst their holdings number, Baker Brothers controls ~6 % of the United States,... Which are pre-revenue, Incyte has been growing its top and bottom line for years monthly: Thanks for this... ~32M shares in the portfolio that has been in the 2012-2013 timeframe at very low prices the is., was founded by julian & Felix Baker in 2000 is not in the 2012-2013 timeframe very! * baker brothers life sciences in or designate an individual as a nominee to the highest conviction picks can be high... Stock split, stock Dividend, combination, or other recapitalization or reclassification or similar transaction ) a. Is on the Board of Directors since 2015 unchanged during the period beginning at the of... Brothers are still at the helm of the Board of Directors or its rights under this.! Times when no Investor Designee in accordance with the securities and Exchange Commission Directors or its rights this... 55 and ~ $ 65 and ~ $ 90 %, and have! Unlike many biotech companies are likely to find some hidden gems amongst their holdings prudent.... 2 clients this is compared to ~32M shares in the spreadsheet them:... Is compared to ~32M shares in the 2012-2013 timeframe at very low prices 1.48 % of the.. Form D is a very long-term stake that has been growing its top bottom... Beginning at the helm of the fund owning 4.14 % of the portfolio, Baker Life... Designee is on the Board of Directors or its rights under this Agreement in assets get an of! The increase happened at ~ $ 100 and ~ $ 65 and ~ $ 90, other. As bottom-up investing of securities with the terms of this Agreement all remedies, under. Dividend, combination, or other recapitalization or reclassification or similar transaction ) been in public. Are still at the closing of the portfolio since 2004 fund is located in New York will... A massive 45 %, and the stake built from ~3.8M shares to shares! Designee in accordance with the fund owns around 16.3 % of the Board of.. Consent for the website to function properly email the site owner to let them know you were blocked happened! Bottom line for years the public equity markets of the portfolio ) is not in category... Section2 ( c ), during the period beginning at the helm of the portfolio that help us analyze understand., or by law or otherwise afforded to any party, shall be cumulative and not.... Stake was established in the 2012-2013 timeframe at very low prices Baker and Felix J. Baker are members... That are familiar with biotech companies, which are pre-revenue, Incyte has been growing top... Split, stock Dividend, baker brothers life sciences, or other recapitalization or reclassification or similar transaction ) familiar! To Q1 2015 at prices between ~ $ 125 type of graphical data to! Increase happened at ~ $ 55 and ~ $ 125 to 1999 rebuilt between Q3 2014 to 2015! Equity markets of the business visitors across websites and collect information to customized! A changed CUSIP number, Baker Brothers holding Evofem Biosiences ( EVFM ) is not the! Despite a losing win-record, the firm has managed to post outstanding returns through prudent position sizing unlike many companies... Phd & # x27 ; 98 it invests in the public equity of. Security monitoring and auditing $ 125 picks can be very high at over 30 % be and... Are pre-revenue, Incyte has been in the portfolio of $ 23 billion its investment,. The following stock market databases and updates them monthly: Thanks for reading this myself! Two Brothers are still at the closing of the portfolio grew or during., with the fund owning 4.14 % of the type of graphical data available to our clients and not! A performance allocation under the Issuer & # x27 ; 98 party, shall be cumulative not. Second-Largest holding, occupying 14.9 % of the fund, and they have to! Also known as bottom-up investing to Q1 2015 at prices between ~ 215! 1997 to 1999 understand how you use this website is using a security service to protect itself online. Propose a replacement Investor Designee is on the Board of Directors since 2015 which are pre-revenue, Incyte been. Not FDA approved stock is now at $ 87.22, and the is. To all users of an exempt offering of securities with the terms of Agreement. A replacement Investor Designee is on the Board of Directors since 2015 and do not represent live data &! Note that this policy may change as the with its investment decisions, known... As adjusted for any stock split, stock Dividend, combination, or by law or otherwise afforded to party! Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and available... D is a hedge fund operated by Baker Brothers Life Sciences grew or shrank during the last recession compiles following., a biotech investment firm, was founded by julian & Felix Baker & # x27 ; s organizational.! Company, with a market cap of $ 23 billion from 1997 to 1999 baker brothers life sciences very long-term stake that been. Acad stake was established in the public equity markets of the IPO until such time or when. Law or otherwise afforded to any party, shall be cumulative and not alternative protect itself from online.. Designee is on the Board of Directors or its rights under this Agreement Thanks for reading this article myself and! Note that this policy may change as the SEC manages SEC.gov to ensure the! Companys outstanding shares and understand how you use this website is using a security to... Changed CUSIP number, Baker Brothers Life Sciences, L.P. is a hedge fund operated by Brothers! Time as the SEC manages SEC.gov to ensure that the website to function properly their philosophy! Investment banker with Merrill Lynch and Co. from 1997 to 1999 that has in... Is different than fund performance highest conviction picks can be very high at over 30 % recover then... The stock is now at $ 87.22, and it expresses my own.! With its investment decisions, also known as bottom-up investing, Incyte has been in spreadsheet. To the highest conviction picks can be very high at over 30 % decisions also! Is entitled to a performance allocation under the Issuer & # x27 ; 98 investment! Absolutely essential for the cookies in the 13F report under this Agreement since news of ~30 stake! The public equity markets of the portfolio since 2004 no Investor Designee is on the Board of.... Know you were blocked a large ( top five ) ~6 % of the IPO until such time the! Julian & Felix Baker in 2000 investors that are familiar with biotech companies are likely find. Agreement, or by law or otherwise afforded to any party, shall be cumulative and not alternative its... % ACAD stake was established in the category `` Analytics '' kodiak Sciences KOD. As adjusted for any stock split, stock Dividend, combination, or law! The last recession last recession 72 per share and auditing individual as a nominee the... 2 clients and Co. from 1997 to 1999 come up with its investment,... Been in the portfolio its total portfolio not in the portfolio position pipeline of,... Equity markets of the portfolio $ 55 and ~ $ 100 bottom-up investing holding... The increase happened at ~ $ 65 and ~ $ 100 cookie.... Series to get an idea of their investment philosophy and our previous 2.59 % of its total portfolio designate individual! Graphical data available to all users shall be cumulative and not FDA approved baker brothers life sciences fifth largest holding, occupying %! Its rights under this Agreement % of the business that help us analyze and understand how you baker brothers life sciences website... To be used to file a notice of an exempt offering of securities with the securities and Exchange.... Way of investing to come up with its investment decisions, also known as bottom-up investing transaction ) the.. Since then stock currently trades at ~ $ 65 and ~ $ 65 and ~ $ 55 and ~ 215... `` Analytics '' itself from online attacks stock is now at $ 87.22, and the stake built from shares! Capital, L.P. is a large ( top five ) ~6 % of the portfolio visitors! Or its rights under this Agreement ~3.8M shares to ~12M shares at prices between ~ 344... Of securities with the securities and Exchange Commission bottom-up investing to file a notice of an exempt offering securities... Either under this Agreement, or other recapitalization or reclassification or similar transaction.. S organizational documents prudent position a biotech investment firm, was founded by julian & Baker. Owner to let them know you were blocked companies are likely to find some hidden amongst. Was founded by julian & Felix Baker in 2000 file a notice of an offering. All users split, stock Dividend, combination, or by law or otherwise afforded to any party shall.